INSULET CORP (PODD)

Sector: Healthcare

Financial Fundamentals

findl.com provides a comprehensive suite of standardized financial statement data and an assortment of calculated metrics sourced directly from SEC filings, and meticulously cleansed and verified, ensuring reliability. To get the complete financial statement history in quarterly and annual resolution for PODD, sign up here.

Income Statement

Revenue

$1.7bn

Gross Profit

$1.2bn

Earning before Tax

$214.6m

Net Income

$206.3m

Net Income Common Shareholders

$206.3m

EPS

2.96

Balance Sheet

Cash

$704.2m

Debt

$1.4bn

Assets

$2.6bn

Liabilities

$1.9bn

Equity

$732.7m

Enterprise Value

$15.9bn

Cash Flow Statement

Net Cash from Operations

$145.7m

Net Cash from Investing

$-0.1bn

Net Cash from Financing

$-13.6m

Net Cash Flow

$14.5m

Free Cash Flow

$36.5m

Free Cash Flow per Share

$0.52

Metrics

Price to Equity

73.44

Price to Equity (Damodaran)

73.30

Price to Book

20.68

Net Margin

0.12

Return on Equity

0.34

Return on Sales

0.15

Get immediate access to 5-years of reference grade data for PODD for free.

Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Company Info

Industry

Medical Devices

Employees

2,600

Address

100 Nagog Park
Acton, MA 01720
United States

Phone

978 600 7000

Website

https://www.insulet.com

Last Updated